#BEGIN_DRUGCARD DB06663

# AHFS_Codes:
Not Available

# ATC_Codes:
H01CB05

# Absorption:
The peak plasma concentration of pasireotide occurs in 0.25-0.5 hours. After administration of single and multiple doses, there is  dose-proportionoal increases in Cmax and AUC.

# Biotransformation:
Metabolism is minimal.

# Brand_Mixtures:
Not Available

# Brand_Names:
Signifor®

# CAS_Registry_Number:
396091-73-9

# ChEBI_ID:
72312

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2008-03-19 10:46:53 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor®, which is used in the treatment of Cushing's disease.

# Dosage_Forms:
Solution	Subcutaneous
Solution	Subcutaneous
Solution	Subcutaneous

# Drug_Category:
Somatostatin Analog

# Drug_Interactions:
Mifepristone	Avoid combination with mifepristone and other moderate to high risk QTc prolonging agents. The combinaton may enhance the QTc-prolonging effect of these drugs.

# Drug_Reference:
12239124	Weckbecker G, Briner U, Lewis I, Bruns C: SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002 Oct;143(10):4123-30.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble in water.

# Food_Interactions:
Since Signifor® is administered subcutaneously, food has no effect.

# GenBank_ID:
Not Available

# Generic_Name:
Pasireotide

# HET_ID:
Not Available

# Half_Life:
The half-life is 12 hours.

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D10147

# LIMS_Drug_ID:
6664

# Mechanism_Of_Action:
Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing's disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Signifor® is an analogue of somatostatin that promotes  reduced levels of cortisol secretion in Cushing's disease patients.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB06663

# Protein_Binding:
Plasma protein binding is 88%.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/signifor-drug.htm

# Salts:
pasireotide diaspartate

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
SOM230

# Synthesis_Reference:
Not Available

# Toxicity:
The most common toxic effects observed are hyperglycemia, cholelithiasis, diarrhea, nausea, headache, abdominal pain, fatigue, and diabetes mellitus.

# Update_Date:
2013-05-16 20:34:36 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Pasireotide

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11980628	Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707-16.
17395978	Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer. 2007 Mar;14(1):91-102.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SSTR1

# Drug_Target_1_GenBank_ID_Gene:
M81829

# Drug_Target_1_GenBank_ID_Protein:
307434

# Drug_Target_1_GeneCard_ID:
SSTR1

# Drug_Target_1_Gene_Name:
SSTR1

# Drug_Target_1_Gene_Sequence:
>1176 bp
ATGTTCCCCAATGGCACCGCCTCCTCTCCTTCCTCCTCTCCTAGCCCCAGCCCGGGCAGC
TGCGGCGAAGGCGGCGGCAGCAGGGGCCCCGGGGCCGGCGCTGCGGACGGCATGGAGGAG
CCAGGGCGAAATGCGTCCCAGAACGGGACCTTGAGCGAGGGCCAGGGCAGCGCCATCCTG
ATCTCTTTCATCTACTCCGTGGTGTGCCTGGTGGGGCTGTGTGGGAACTCTATGGTCATC
TACGTGATCCTGCGCTATGCCAAGATGAAGACGGCCACCAACATCTACATCCTAAATCTG
GCCATTGCTGATGAGCTGCTCATGCTCAGCGTGCCCTTCCTAGTCACCTCCACGTTGTTG
CGCCACTGGCCCTTCGGTGCGCTGCTCTGCCGCCTCGTGCTCAGCGTGGACGCGGTCAAC
ATGTTCACCAGCATCTACTGTCTGACTGTGCTCAGCGTGGACCGCTACGTGGCCGTGGTG
CATCCCATCAAGGCGGCCCGCTACCGCCGGCCCACCGTGGCCAAGGTAGTAAACCTGGGC
GTGTGGGTGCTATCGCTGCTCGTCATCCTGCCCATCGTGGTCTTCTCTCGCACCGCGGCC
AACAGCGACGGCACGGTGGCTTGCAACATGCTCATGCCAGAGCCCGCTCAACGCTGGCTG
GTGGGCTTCGTGTTGTACACATTTCTCATGGGCTTCCTGCTGCCCGTGGGGGCTATCTGC
CTGTGCTACGTGCTCATCATTGCTAAGATGCGCATGGTGGCCCTCAAGGCCGGCTGGCAG
CAGCGCAAGCGCTCGGAGCGCAAGATCACCTTAATGGTGATGATGGTGGTGATGGTGTTT
GTCATCTGCTGGATGCCTTTCTACGTGGTGCAGCTGGTTAACGTGTTTGCTGAGCAGGAC
GACGCCACGGTGAGTCAGCTGTCGGTCATCCTCGGCTATGCCAACAGCTGCGCCAACCCC
ATCCTCTATGGCTTTCTCTCAGACAACTTCAAGCGCTCTTTCCAACGCATCCTATGCCTC
AGCTGGATGGACAACGCCGCGGAGGAGCCGGTTGACTATTACGCCACCGCGCTCAAGAGC
CGTGCCTACAGTGTGGAAGACTTCCAACCTGAGAACCTGGAGTCCGGCGGCGTCTTCCGT
AATGGCACCTGCACGTCCCGGATCACGACGCTCTGA

# Drug_Target_1_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_1_General_References:
10734105	Schwarzler A, Kreienkamp HJ, Richter D: Interaction of the somatostatin receptor subtype 1 with the human homolog of the Shk1 kinase-binding protein from yeast. J Biol Chem. 2000 Mar 31;275(13):9557-62.
1346068	Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5.

# Drug_Target_1_HGNC_ID:
HGNC:11330

# Drug_Target_1_HPRD_ID:
01673

# Drug_Target_1_ID:
503

# Drug_Target_1_Locus:
14q13

# Drug_Target_1_Molecular_Weight:
42687

# Drug_Target_1_Name:
Somatostatin receptor type 1

# Drug_Target_1_Number_of_Residues:
391

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_1_Protein_Sequence:
>Somatostatin receptor type 1
MFPNGTASSPSSSPSPSPGSCGEGGGSRGPGAGAADGMEEPGRNASQNGTLSEGQGSAIL
ISFIYSVVCLVGLCGNSMVIYVILRYAKMKTATNIYILNLAIADELLMLSVPFLVTSTLL
RHWPFGALLCRLVLSVDAVNMFTSIYCLTVLSVDRYVAVVHPIKAARYRRPTVAKVVNLG
VWVLSLLVILPIVVFSRTAANSDGTVACNMLMPEPAQRWLVGFVLYTFLMGFLLPVGAIC
LCYVLIIAKMRMVALKAGWQQRKRSERKITLMVMMVVMVFVICWMPFYVVQLVNVFAEQD
DATVSQLSVILGYANSCANPILYGFLSDNFKRSFQRILCLSWMDNAAEEPVDYYATALKS
RAYSVEDFQPENLESGGVFRNGTCTSRITTL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins

# Drug_Target_1_SwissProt_ID:
P30872

# Drug_Target_1_SwissProt_Name:
SSR1_HUMAN

# Drug_Target_1_Synonyms:
SRIF-2
SS1R

# Drug_Target_1_Theoretical_pI:
8.40

# Drug_Target_1_Transmembrane_Regions:
57-84
95-120
132-153
176-196
220-244
271-296
304-327

# Drug_Target_2_Cellular_Location:
Cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11980628	Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707-16.
17395978	Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer. 2007 Mar;14(1):91-102.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SSTR2

# Drug_Target_2_GenBank_ID_Gene:
BC095495

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
SSTR2

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
10551867	Zitzer H, Honck HH, Bachner D, Richter D, Kreienkamp HJ: Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain. J Biol Chem. 1999 Nov 12;274(46):32997-3001.
10619399	Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM: Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol. 1999 Nov 25;157(1-2):75-85.
1346068	Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S: Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5.
8386508	Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB: Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993 Apr 15;192(1):288-94.

# Drug_Target_2_HGNC_ID:
HGNC:11331

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6008

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
41333

# Drug_Target_2_Name:
Somatostatin receptor type 2

# Drug_Target_2_Number_of_Residues:
369

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_2_Protein_Sequence:
>Somatostatin receptor type 2
MDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIYFVVCIIGLCG
NTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLAMQVALVHWPFGKAICRVVMT
VDGINQFTSIFCLTVMSIDRYLAVVHPIKSAKWRRPRTAKMITMAVWGVSLLVILPIMIY
AGLRSNQWGRSSCTINWPGESGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGI
RVGSSKRKKSEKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVL
TYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRLNETTETQRTL
LNGDLQTSI

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Receptor for somatostatins-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. In RIN-5F cells, this receptor inhibits calcium entry by suppressing voltage dependent calcium-channels

# Drug_Target_2_SwissProt_ID:
P30874

# Drug_Target_2_SwissProt_Name:
SSR2_HUMAN

# Drug_Target_2_Synonyms:
SRIF-1
SS2R

# Drug_Target_2_Theoretical_pI:
9.18

# Drug_Target_2_Transmembrane_Regions:
44-67
79-103
119-138
162-181
208-229
254-278
289-303

# Drug_Target_3_Cellular_Location:
Cell membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11980628	Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707-16.
17395978	Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer. 2007 Mar;14(1):91-102.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
SSTR3

# Drug_Target_3_GenBank_ID_Gene:
BC096829

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
SSTR3

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
1337145	Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S: Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol. 1992 Dec;6(12):2136-42.
8097479	Corness JD, Demchyshyn LL, Seeman P, Van Tol HH, Srikant CB, Kent G, Patel YC, Niznik HB: A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 1993 Apr 26;321(2-3):279-84.

# Drug_Target_3_HGNC_ID:
HGNC:11332

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6009

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
45848

# Drug_Target_3_Name:
Somatostatin receptor type 3

# Drug_Target_3_Number_of_Residues:
418

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Somatostatin receptor type 3
MDMLHPSSVSTTSEPENASSAWPPDATLGNVSAGPSPAGLAVSGVLIPLVYLVVCVVGLL
GNSLVIYVVLRHTASPSVTNVYILNLALADELFMLGLPFLAAQNALSYWPFGSLMCRLVM
AVDGINQFTSIFCLTVMSVDRYLAVVHPTRSARWRTAPVARTVSAAVWVASAVVVLPVVV
FSGVPRGMSTCHMQWPEPAAAWRAGFIIYTAALGFFGPLLVICLCYLLIVVKVRSAGRRV
WAPSCQRRRRSERRVTRMVVAVVALFVLCWMPFYVLNIVNVVCPLPEEPAFFGLYFLVVA
LPYANSCANPILYGFLSYRFKQGFRRVLLRPSRRVRSQEPTVGPPEKTEEEDEEEEDGEE
SREGGKGKEMNGRVSQITQPGTSGQERPPSRVASKEQQLLPQEASTGEKSSTMRISYL

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Receptor for somatostatins-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase

# Drug_Target_3_SwissProt_ID:
P32745

# Drug_Target_3_SwissProt_Name:
SSR3_HUMAN

# Drug_Target_3_Synonyms:
SS3R
SSR-28

# Drug_Target_3_Theoretical_pI:
8.67

# Drug_Target_3_Transmembrane_Regions:
44-69
80-101
117-138
162-181
206-231
258-279
294-316

# Drug_Target_4_Cellular_Location:
Membrane

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
11980628	Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707-16.
17395978	Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer. 2007 Mar;14(1):91-102.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
SSTR5

# Drug_Target_4_GenBank_ID_Gene:
L14865

# Drug_Target_4_GenBank_ID_Protein:
431095

# Drug_Target_4_GeneCard_ID:
SSTR5

# Drug_Target_4_Gene_Name:
SSTR5

# Drug_Target_4_Gene_Sequence:
>1092 bp
ATGGAGCCCCTGTTCCCAGCCTCCACGCCCAGCTGGAACGCCTCCTCCCCGGGGGCTGCC
TCTGGAGGCGGTGACAACAGGACGCTGGTGGGGCCGGCGCCCTCGGCAGGGGCCCGGGCG
GTGCTGGTGCCCGTGCTGTACCTGCTGGTGTGTGCGGCCGGGCTGGGCGGGAACACGCTG
GTCATCTACGTGGTGCTGCGGTTCGCCAAGATGAAGACCGTCACCAACATCTACATTCTC
AACCTGGCAGTGGCCGACGTCCTGTACATGCTGGGGCTGCCTTTCCTGGCCACGCAGAAC
GCCGCGTCCTTCTGGCCCTTCGGCCCCGTCCTGTGCCGCCTGGTCATGACGCTGGACGGC
GTCAACCAGTTCACCAGTGTCTTCTGCCTGACAGTCATGAGCGTGGACCGCTACCTGGCA
GTGGTGCACCCGCTGAGCTCGGCCCGCTGGCGCCGCCCGCGTGTGGCCAAGCTGGCGAGC
GCCGCCGCCTGGGTCCTGTCTCTGTGCATGTCGCTGCCGCTCTTGGTGTTCGCGGACGTG
CAGGAGGGCGGTACCTGCAACGCCAGCTGGCCGGAGCCCGTGGGGCTGTGGGGCGCCGTC
TTCATCATCTACACGGCCGTGCTGGGCTTCTTCGCGCCGCTGCTGGTCATCTGCCTGTGC
TACCTGCTCATCGTGGTGAAGGTGAGGGCGGCGGGCGTGCGCGTGGGCTGCGTGCGGCGG
CGCTCGGAGCGGAAGGTGACGCGCATGGTGTTGGTGGTGGTGCTGGTGTTTGCGGGATGT
TGGCTGCCCTTCTTCACCGTCAACATCGTCAACCTGGCGGTTGCGCTGCCCCAGGAGCCC
GCCTCCGCCGGCCTCTACTTCTTCGTGGTCATCCTCTCCTACGCCAACAGCTGTGCCAAC
CCCGTCCTCTACGGCTTCCTCTCGGACAACTTCCGCCAGAGCTTCCAGAAGGTTCTGTGC
CTCCGCAAGGGCTCTGGTGCCAAGGACGCTGACGCCACGGAGCCGCGTCCAGACAGGATC
CGGCAGCAGCAGGAGGCCACGCGCCCGCGCACCGCCGCAGCCAACGGGCTTATGCAGACC
AGCAAGCTGTGA

# Drug_Target_4_General_Function:
Not Available

# Drug_Target_4_General_References:
11157797	Daniels RJ, Peden JF, Lloyd C, Horsley SW, Clark K, Tufarelli C, Kearney L, Buckle VJ, Doggett NA, Flint J, Higgs DR: Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16. Hum Mol Genet. 2001 Feb 15;10(4):339-52.
7908405	Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB, Patel YC: Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol. 1994 Mar;45(3):417-27.
8078491	O'Carroll AM, Raynor K, Lolait SJ, Reisine T: Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol. 1994 Aug;46(2):291-8.
8373420	Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S, et al.: Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52.

# Drug_Target_4_HGNC_ID:
HGNC:11334

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3872

# Drug_Target_4_Locus:
16p13.3

# Drug_Target_4_Molecular_Weight:
39203

# Drug_Target_4_Name:
Somatostatin receptor type 5

# Drug_Target_4_Number_of_Residues:
364

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_4_Protein_Sequence:
>Somatostatin receptor type 5
MEPLFPASTPSWNASSPGAASGGGDNRTLVGPAPSAGARAVLVPVLYLLVCAAGLGGNTL
VIYVVLRFAKMKTVTNIYILNLAVADVLYMLGLPFLATQNAASFWPFGPVLCRLVMTLDG
VNQFTSVFCLTVMSVDRYLAVVHPLSSARWRRPRVAKLASAAAWVLSLCMSLPLLVFADV
QEGGTCNASWPEPVGLWGAVFIIYTAVLGFFAPLLVICLCYLLIVVKVRAAGVRVGCVRR
RSERKVTRMVLVVVLVFAGCWLPFFTVNIVNLAVALPQEPASAGLYFFVVILSYANSCAN
PVLYGFLSDNFRQSFQKVLCLRKGSGAKDADATEPRPDRIRQQQEATPPAHRAAANGLMQ
TSKL

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase

# Drug_Target_4_SwissProt_ID:
P35346

# Drug_Target_4_SwissProt_Name:
SSR5_HUMAN

# Drug_Target_4_Synonyms:
SS5R

# Drug_Target_4_Theoretical_pI:
9.72

# Drug_Target_4_Transmembrane_Regions:
39-66
77-101
114-135
158-178
198-222
248-273
284-308

#END_DRUGCARD DB06663
